Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast 

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast 

Business & Finance

Reuters was two-and-a-half minutes ahead of rivals on Eli Lilly’s unscheduled trading update, which showed fourth-quarter sales of its weight-loss drug Zepbound would miss Wall Street estimates. The drugmaker’s shares slumped 8% on the news.

Article Tags

Topics of Interest: Business & Finance

Type: Reuters Best

Sectors: Business & Finance

Regions: Americas

Win Types: Speed

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Important Regional Story

Source link

info@fzeetechz.com Avatar

Leave a Reply

Your email address will not be published. Required fields are marked *

No comments to show.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

[contact-form-7 id=”82dec49″ title=”Newsletter”]

By signing up, you agree to the our terms and our Privacy Policy agreement.